

Patent Number:

United States Patent [19]

Chan et al.

Date of Patent: [45]

Sep. 14, 1999

5,952,527

CHIRAL AMINOPHOSPHINES

Inventors: Albert Sun-Chi Chan; Fu-Yao Zhang,

both of Kowloon, The Hong Kong Special Administrative Region of the People's Republic of China

[73] Assignee: The Hong Kong Polytechnic

University, Kowloon, The Hong Kong Special Administrative Region of the People's Republic of China

[21] Appl. No.: 09/241,091

[22] Filed: Feb. 1, 1999

Related U.S. Application Data

Division of application No. 08/988,377, Dec. 10, 1997, Pat. [62] No. 5,919,981.

[52] [58] **Field of Search** 564/12; 556/20

[56] References Cited

PUBLICATIONS

Kagan et al., "Reduction Asymetrique Catalysee Par Des Complexes De Metaux De Transition", Journal of Organometallic Chemistry, vol. 90, 1975, pp. 353-365. Sinou et al., "Catalyse Asymetrique Par Le Complexe Cationique [Rh (COD) (+) Diopl]*CLO₄-", Journal of Organometallic Chemistry, vol. 114, 1976, pp. 325-337.

Samuel et al., "Phellanphos and Nopaphos, New Diphosphines for Asymmetric Catalysis", Nouveau Journal De Chimie, vol. 5, No. 1, 1981, pp. 15-20.

Burk et al., "A Convenient Asymmetric Synthesis of α-1-Arylalkylamines through the Enantioselective Hydrogenation oif Enamides", J. Am. Chem. Soc., vol. 118, 1996, pp. 5142-5143.

Primary Examiner—Samuel Barts Attorney, Agent, or Firm-Leydig, Voit & Mayer, Ltd.

ABSTRACT

[11]

This invention relates to (R)- and (S)-5,5',6,6',7,7',8,8'octahydro-1,1'-binaphthyl-2,2'-diamine (R-1 and S-1) and (R)- and (S)-2,2'-bis(diarylphospinoamino)-5,5',6,6',7,7',8, 8'-octahydro-1,1'-binaphthyl (R-2 and S-2) and (R)- and (S)-2,2'-bis(diaklphospinoamino)-5,5',6,6',7,7',8,8'octahydro-1,1'-binaphthyl (R-3 and S-3); to a process for the preparation of R-1 and S-1 in which (R) or (S)-1,1'binaphthyl-2,2'-diamine is partially hydrogenated in the presence of Adam's catalyst (5–20 wt/o of starting material) at 20-100° C. for 20-100 hours in glacial acetic acid (solvent); to a process for the preparation of R-2, S-2, R-3 and S-3 in which R-1 or S-1 is reacted with chlorodiarylphosphine or chlorodialkylphosphine in the presence of n-butyllithium; and to the rhodium complexes containing 2 or 3 as effective catalysts for the asymmetric hydrogenation of prochiral substrates such as olefins to produce higher valued chiral products; and to the asymmetric catalytic hydrogenation of enamides under mild conditions using the Rh-(2) or Rh-(3) as catalyst with chemical yields as high as 100% and enantiomeric excess (e.e.) as high as 99%.

5 Claims, No Drawings

CHIRAL AMINOPHOSPHINES

This disclosure is a division of patent application Ser. No. 08/988,377, filed Dec. 10, 1997 now U.S. Pat. No. $_5$ 5,919,981.

FIELD OF INVENTION

This invention relates to a new class of organic compounds which are useful as auxiliaries in asymmetric synthesis for the production of a variety of chiral organic compounds, such as chiral amino acids, amides, and amines.

BACKGROUND

Chiral amines are an important class of organic compounds which can be used as resolving reagents, chiral auxiliaries, and intermediates in the synthesis of a variety of biologically active molecules. Asymmetric catalytic hydrogenation potentially provides a very efficient and convenient route to chiral amines; however, so far only limited success has been achieved. The well known chiral diphosphine ligands, such as, DIOP (J. Organomet Chem. 1975, 90, 353) 25 and its derivatives (J. Organomet. Chem. 1976, 114, 325), PHELLANPHOS and NOPAPHOS (Nouv. J Chim. 1981, 5, 15), were used as chiral ligands in the asymmetric catalytic hydrogenation of α-phenylenamide. However, the enantiomeric excess (e.e.) values of the products were quite low. Recently, DUPHOS and BPE ligands (J. Am. Chem. Soc. 1996, 118, 5142) have been reported to be effective in the hydrogenation of arylenamides leading to high enantioselectivities (>90% e.e.). Unfortunately, with these catalysts 35 the rate of reaction was too slow and the required reaction time was long.

SUMMARY OF THE INVENTION

We recently synthesized a class of novel aminophosphine ligands and surprisingly found that the rhodium catalysts containing this new class of aminophosphines were extremely active and enantioselective in the asymmetric hydrogenation of enamides. Quantitative chemical yields and up to 99% e.e. were obtained under very mild hydrogenation conditions (as low as one atmosphere of hydrogen pressure at 0° C. in 30–120 minutes). The catalysts were also highly active and enantioselective in the asymmetric hydrogenation of 2-acylamidoacrylic acids and their derivatives leading to high valued amino acids in high optical purity. The Preparation of the rhodium catalyst is convenient. All of these advantages make the novel aminophosphines attractive for industrial applications.

This present invention encompasses the hydrogenation reactions in which the catalyst thereof is a rhodium complex containing a chiral aminophosphine ligand of the present invention.

This present invention also relates to new chiral diamines R-1 and S-1, new chiral aminophosphines R-2, S-2, R-3 and S-3 and their synthetic routes.

The new chiral diamines of this invention have the following structures:

2

$$NH_2$$
 NH_2
 NH_2
 NH_2
 NH_2
 NH_2
 NH_2
 NH_2

The novel, optically active ligands of this invention have the following structures:

NHPR₂
NHPR₂
NHPR₂

$$R$$
-2 and R -3
 S -2 and S -3

wherein:

(a) for ligands R-2 and S-2, R is chosen from the following groups:

45 in which R' and R" are either the same or different with each representing a straight chain or branched alkyl group having from 1 to 6 carbon atoms or an alkoxyl group having from 1 to 6 carbon atoms; and

(b) for ligands R-3 and S-3, R is a cycloalkyl group having from 5 to 8 carbon atoms.

The new chiral diamine R-1 or S-1 was synthesized by partial hydrogenation of (R)- or (S)-1,1-binaphthyl-2,2'-diamine and the new chiral ligand R-2, S-2, R-3 or S-3 was prepared by the reaction of the new chiral diamine R-1 or S-1 with chlorodiarylphosphine or chlorodialkylphosphine after treatment with n-butyllithium.

For the purposes of this invention, the catalysts can be prepared in situ by the reaction of the pure optical isomer of R-2, S-2, R-3 or S-3 with [Rh(COD)Cl]₂ (where COD represents cyclooctadiene) in a suitable organic solvent such as tetrahydrofuran (THF), acetone, benzene, etc. to produce the rhodium complex containing R-2, S-2, R-3 or S-3. The chloride anion can be replaced with a bromide or iodide ion. Alternatively, AgBF₄ can be added to the solution of Rh(COD)(2)Cl or Rh(COD)(3)Cl to produce [Rh(COD)(2)] BF₄ or [Rh(COD)(3)]BF₄, wherein (2) is the R-2 or S-2 and (3) is the R-3 or S-3 ligand The BF₄⁻ ion can be replaced by

30

3

other non-coordinating or weakly coordinating anions such as ClO₄-, PF₆-, etc.

For the purposes of this invention, the rhodium complexes containing R-2, S-2, R-3 or S-3 can be used as catalysts in the hydrogenation of a-arylenamides and 2-acylamidoacrylic acids and their derivatives. Some illustrative examples of the precursors for the asymmetric hydrogenation are shown below:

 α -Arylenamide:

$$R^3$$
 C
 R^5
 R^5
 R^5
 R^6
 R^4
 R^6
 R^6

R³=H, or=CH₃, CH₂CH₃, Ph, naphthyl, etc. when R⁵=H R⁴=Ph, o-MePh, m-MePh, p-MePh, p-FPh, p-ClPh, p-CF₃Ph,

 R^5 =H, or=CH₃, CH₂CH₃, Ph, naphthyl, etc. when R^3 =H 2-Acylamidoacrylic acid and its derivatives:

$$C = C$$
 $COOR^7$
 $C = C$
 $COOR^7$
 $COOR^8$

 R^6 =H, Ph, o-ClPh, m-ClPh, p-ClPh, p-BrPh, p-FPh, $_{35}$ p-MeOPh, p-MePh, p-NO₂Ph,

$$\begin{array}{c} H \\ Ph \end{array} \\ C = C \\ H \end{array}, \begin{array}{c} O \\ O \\ O \end{array} \\ AcO \\ OMe \end{array}$$

 R^7 =H, CH_3 R⁸=CH₃, Ph

The following examples of experiments are provided to illustrate but not to limit the scope of the usefulness of this invention. In said examples, the following abbreviations are used: THF=tetrahydrofuran, COD=cyclootadiene, e.e.= enantiomeric excess.

EXAMPLE 1

Preparation of (R)-5,5',6,6',7,7',8,8'-octahydro-1,1'binaphthyl-2,2'-diamine (R-1)

200 mg (R)-1,1'-binaphthyl-2,2'-diamine (purchased from Aldrich Chemical Company), 20 mg PtO₂ and 20 mL glacial acetic acid were charged into a 50 mL autoclave equipped with a magnetic stirring bar. The autoclave was closed and 1,000 KPa hydrogen gas was charged. The solution was 65 stirred with a magnetic stirrer for 120 hours at room temperature. After releasing the hydrogen gas and removing the

solid catalyst by filtration, the mixture was neutralized with aqueous NaHCO₃ solution followed by extraction with 50 mL ethyl acetate three times. The combined extracts were dried with sodium sulfate and the solvent was removed with a rotary evaporator to give 210 mg of crude product (R-1). The crude product was purified by crystallization with 5 mL ethyl acetate and 15 mL hexane to give 180 mg crystals of R-1 (87.5% of theoretical yield). The analytical data for R-1 were as follows:

m.p.: 210° C. (decomposed); $[\alpha]_D$ =133° (c=1.0, pyridine); ¹H-NMR (400 MHz, CDCl₃) δ : 1.61–1.73(m, 8H); 2.16–2.28(m, 4H); 2.70(m, 4H); 3.07(s, 4H); 6.60(d, J=8.2 Hz); 6.90(d, J=8.0 Hz). ¹³C-NMR (100 MHz,CDCl₃) δ: 23.6, 27.4, 29.7, 113.5, 122.4, 128.0, 129.6, 136.6, 141.9.

EXAMPLE 2

Preparation of (S)-5,5',6,6',7,7',8,8'-octahydro-1,1'binaphthyl-2,2'-diamine (S-1)

The procedure was the same as in example 1 except that (S)-1,1'-binaphthyl-2,2'-diamine was used as starting material instead of (R)-1,1'-binaphthyl-2,2'-diamine. The analytical data for S-1 were as follows:

m.p.: 210° C. (decomposed); $[\alpha]_D = -133^\circ$ (c=1.0, pyridine); ¹H-NMR (400 MHz, CDCl₃) δ: 1.61–1.73(m, 8H); 2.16–2.28(m, 4H); 2.70(m, 4H); 3.07(s, 4H); 6.60(J= 8.2 Hz); 6.90(d, J=8.0 Hz). ¹³C-NMR (100 MHz, CDCl₃) δ: 23.6, 27.4, 29.7, 113.5, 122.4,128.0,129.6,136.6,141.9.

EXAMPLE 3

Preparation of (R)-2,2'-bis (diphenylphospinoamino)-5,5'6,6',7,7',8,8'octahydro-1,1'-binaphthyl (R-2a)

(R)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl-2,2'diamine (R-1) (200 mg, 0.7 mmol) in THF (20 mL) was charged to a 50 mL flask under a dinitrogen atmosphere. This flask was cooled to -30° C. and into the solution was added a solution of n-butyllithium in hexane (0.88 mL of 1.6M solution, 1.4 mmol) in a dropwise manner. The mixture was stirred for two hours at -30° C. with a magnetic stirrer. Then a solution of chlorodiphenylphosphine (0.32 mL, 1.8 mmol) in THF (5 mL) was added dropwise. The system was allowed to stir for 5 hours and the temperature was raised to room temperature. The solution was filtered to remove the solid. The THF solvent was removed in vacuo to give 420 mg of R-2a. The crude product was dissolved in 2 mL dichloromethane and 10 mL of diethyl ether was added to the solution. The final solution was kept at -30° C. for 24 hours to allow the growth of pure crystals of R-2a. After filtration and drying in vacuo, 390 mg of white, needle-like crystals of R-2a were obtained (85% of theoretical yield). The analytical data for R-2a were as follows:

m.p.: 137–139° C.; $[\alpha]_D = -47^\circ$ (c=1.0, CH₂Cl₂); ¹H-NMR (400 MHz, CDCl₃) δ: 1.58(m, 8H); 2.10(m, 4H); 2.67(m, 4H; 4.27(d, J_{P-H} =7.0 Hz, 2H; 6.98(d, J_{H-H} =8.34 Hz, 2H); 7.24(m, 22H). ¹³C-NMR (100 MHz, CDCl₃) δ: 23.0, 23.1, 27.3, 29.3, 112.5, 112.7, 123.2, 128.2, 128.3, 128.4, 128.7, 128.9, 129.6, 130.2, 130.4, 130.8, 131.0, 136.1, 140.5, 140.6, 141.0, 141.2, 141.7, 141.9. ³¹P-NMR(160 MHz, CDCl₃) δ:27.25 ppm.

EXAMPLE 4

Preparation of (S)-2,2'-bis(diphenylphospinoamino)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl (S-2a)

The procedure was the same as in example 3 except that (S)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl-2,2'-

diamine (S-1) was used as starting material instead of (R)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl-2,2'-diamine (R-1). The analytical data for S-2a were as follows: m.p.: 137–139° C.; $[\alpha]_D$ =47° (c=1.0, CH₂Cl₂); ¹H-NMR (400 MHz, CDCl₃) &: 1.58(m, 8H); 2.10(m, 4H); 2.67(m, 4H); 4.27(d, J_{P_3H} =7.0 Hz, 2H); 6.98(d, J_{H_2H} =8.34 Hz, 2H); 7.24(m, 22H). ¹³C-NMR (100 MHz, CDCl₃) &: 23.0, 23.1, 27.3, 29.3, 112.5, 112.7, 123.2, 128.2, 128.3, 128.4, 128.7, 128.9, 129.6, 130.2, 130.4, 130.8, 131.0, 136.1, 140.5, 140.6, 141.0, 141.2, 141.7, 141.9. ³¹P-NMR (160 MHz, CDCl₃) &:27.25 ppm.

EXAMPLE 5

Preparation of [Rh(COD)(R-2a)]BF₄ Complex

[Rh(COD)Cl]₂ (purchased from Stream Chemicals, Inc., Newburyport, Mass.) (5.0 mg, 0.01 mmol) and AgBF₄(4.0 15 mg, 0.03 mmol) in THF (2 mL) were stirred at room temperature for 30 minutes under nitrogen atmosphere. The solution was filtered to remove the solid AgCl. After the addition of R-2a (13 mg, 0.02 mmol) in THF (3 mL) to the solution, [Rh(COD)(R-2a)]BF₄ in THF was obtained in situ (4×10⁻⁶ mol/mL). ³¹P-NMR (160 MHz, THF): 63.45(d, J_{Rh-P} =155.1 Hz).

EXAMPLE 6

Preparation of [R(COD)(S-2a)]BF₄ Complex

The THF solution of [Rh(COD)(S-2a)]BF₄ (4×10^{-6} mol/mL) was prepared in situ with the same procedure as in example 5 by using S-2a instead of R-2a. ³¹P-NMR (160MHz, THF): 63.45(d, J_{Rh-P}=155.1 Hz).

EXAMPLE 7

Asymmetric Hydrogenation of N-acetyl-1phenylethenamine Catalyzed by [Rh(COD)(R-2a)] BF₄ Complex at 0°C.

A THF solution of [Rh(COD)(R-2a)]BF₄ (300 μ L, 0.0012 mmol) (prepared in example 5) and N-acetyl-1phenylethenamine (0.039 g, 0.24 mmol) in THF(10 mL) were charged to a 50 mL autoclave. The hydrogenation was carried out under 100 KPa of hydrogen pressure at 0° C. for 30 minutes. A portion of the reaction mixture was analyzed by gas chromatography to determine the product composition. Complete conversion (100%) of the starting material to the hydrogenation product and 96.8% e.e. of (R)-N-acetyl-1-phenylethylamine were observed. Activated carbon (5 mg) was added to the solution and the mixture was stirred for 15 minutes. After filtration, the THF solvent was evaporated to give a white solid of (R)-N-acetyl-1-phenylethylamine 45 (0.038 g), 96.8% e.e., yield 97% (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 8

Asymmetric hydrogenation of N-acetyl-1-phenylethenamine Catalyzed by [Rh(COD)(R-2a)] BF₄ Complex at 0°C.

The hydrogenation was carried out through the same procedure as in example 7 using [Rh(COD)(S-2a)]BF₄ 55 (prepared in example 6) instead of [Rh(COD)(R-2a)]BF₄ (prepared in example 5) to give the product (s)-N-acetyl-1-phenylethylamine, 96.8% e.e., 97% yield (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 9

Asymmetric Hydrogenation of N-acetyl-1phenylethenamine Catalyzed by [Rh(COD)(R-2a)] BF₄ Complex at Room Temperature

The hydrogenation was carried out through the same procedure as in example 7 at room temperature (25° C.)

6

instead of 0° C. to give the product (R)-N-acetyl-1-phenylethylamine in 92.1% e.e., 98% yield (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 10

Asymmetric Hydrogenation of N-acetyl-1phenylethenamine Catalyzed by [Rh(COD)(S-2a)] BF₄ Complex at Room Temperature

The hydrogenation was carried out through the same procedure as in example 7 at room temperature instead of 0° C. to give the product (S)-N-acetyl-1-phenylethylamine, 92.4% e.e., 98% yield (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 11

Asymmetric Hydrogenation of E/Z Isomers (3:2) of N-acetyl-1-(4'-chlorophenyl)-propenamine Catalyzed by [Rh(COD)(R-2a)]BF₄ Complex at 0°

THF solution of $[Rh(COD)(R-2a)]BF_4$ (300 μ L, 0.0012 mmol) (prepared in example 5) and N-acetyl-1-(4'chlorophenyl)-propenamine(0.047 g, 0.24 mmol) in THF(10 mL) were charged to a 50 mL autoclave. The hydrogenation was carried out under 100 KPa of hydrogen pressure at 0° C. for 2 hours. A portion of the reaction mixture was analyzed 30 by gas chromatography to determine the product composition. Complete conversion (100%) of the starting material to the hydrogenation product and 80.3% e.e. of (R)-N-acetyl-1-(4'-chlorophenyl)propylamine were observed. Activated carbon (5 mg) was added to the solution and the mixture was stirred for 15 minutes. After filtration, the THF solvent was evaporated to give a white solid of (R)-N-acetyl-1-(4'chlorophenyl)propylamine (0.045 g), 80.3% e.e., yield 96% (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 12

Asymmetric Hydrogenation of E/Z Isomers (3:2) of N-acetyl-1-(4'-chlorophenyl)-propenamine Catalyzed by [Rh(COD)(S-2a)]BF₄ Complex at 0° C.

The hydrogenation was carried out through the same procedure as in example 11 using [Rh(COD)(S-2a)]BF₄ (prepared in example 6) instead of [Rh(COD)(R-2a)]BF₄ (prepared in example 5) to give the product (S)-N-acetyl-1-(4'-chlorophenyl)propylamine, 80.2% e.e., 96% yield (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 13

Asymmetric Hydrogenation of methyl (Z)-2-acetamidocinnamate Catalyzed by [Rh(COD)(R-2a)]BF₄ Complex at Room Temperature

A THF solution of [Rh(COD)(R-2a)]BF₄ (600 μ L, 0.0024 mmol) (prepared in example 5) and methyl (Z)-2-acetamidocinnamate (0.053 g, 0.24 mmol) in THF (10 mL) were charged to a 50 mL autoclave. The hydrogenation was carried out under 200 KPa of hydrogen pressure at room temperature for 10 minutes. A portion of the reaction mixture was analyzed by gas chromatography to determine the product composition. 100% conversion of the starting material to the hydrogenation product and 95.8% e.e. of methyl

(R)-2-acetamido-3-phenylpropionate were observed. Activated carbon (5 mg) was added to the solution and the mixture was stirred for 15 minutes. After filtration, the THF solvent was evaporated to give a white solid of methyl (R)-2-acetamido-3-phenylpropanoate (0.050 g), 95.8% e.e., yield 95% (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 14

Asymmetric Hydrogenation of Methyl (Z)-2-acetamidocinnamate Catalyzed by [Rh(COD)(S-2a)]
BF₄ Complex at Room Temperature

The hydrogenation was carried out through the same 15 procedure as in example 13 at room temperature except that $[Rh(COD)(S-2a)]BF_4$ was used as catalyst instead of $[Rh(COD)(R-2a)]BF_4$ to give the product methyl (S)-2-acetamido-3-phenylpropionate in 95.6% e.e., 95% yield (The enantiomeric excess was determined by chiral capillary $_{20}$ GC using a Chrompack Chirasil-L-Val column.)

EXAMPLE 15

Asymmetric Hydrogenation of N-acetamidoacrylic Acid Catalyzed by [Rh(COD)(R-2a)]BF₄ Complex at Room Temperature

A THF solution of [Rh(COD)(R-2a)]BF₄ (600 μ L, 0.0024 mmol) (prepared in example 5) and N-acetamidoacrylic acid (0.031 g, 0.24 mmol) in ethanol (10 mL) were charged to a 50 mL autoclave. The hydrogenation was carried out under

8

200 KPa of hydrogen pressure at room temperature for 10 minutes. A portion of the reaction mixture was analyzed by gas chromatography to determine the product composition. 100% conversion of the starting material to the hydrogenation product and 99.0% e.e. of (R)-acetamidopropionic acid were observed. Activated carbon (2 mg) was added to the solution and the mixture was stirred for 15 minutes. After filtration, the solvent was evaporated to give a white solid of (R)-acetamido-propionic acid (0.029 g), 99.0% e.e., yield 94% (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column after converting the product to methyl ester.)

EXAMPLE 16

Asymmetric Hydrogenation of N-acetamidoacrylic Acid Catalyzed by [Rh(COD)(S-2a)]BF₄ Complex at Room Temperature

The hydrogenation was carried out through the same procedure as in example 15 at room temperature except that [Rh(COD)(S-2a)]BF₄ as catalyst was used instead of [Rh(COD)(R-2a)]BF₄ to give the product (S)-acetamidopropionic acid, 99.0% e.e., 94% yield (The enantiomeric excess was determined by chiral capillary GC using a Chrompack Chirasil-L-Val column after converting the product to methyl ester.)

EXAMPLE 17

Other examples of hydrogenation of enamides are shown below:

	I	H	, R ⁵	$^{\mathrm{H}}$ $^{\mathrm{R}^{5}}$				
		`c 	<u>.</u>	Cat*	н	Н		
	I	\mathcal{R}^4	NHCOCH ₃		R^4	NHCOCH	I ₃	
Entry	\mathbb{R}^4	R ⁵	Cat.	T (° C.)	Time (min)	Conv. (%)	e.e. (%)	Confi
1	C_6H_5	Н	[Rh(COD)(R-2a)]BF ₄	RT	10	100	92.1	R
2	C_6H_5	Η	[Rh(COD)(S-2a)]BF ₄	RT	10	100	92.1	S
3	C_6H_5	Η	[Rh(COD)(R-2a)]BF ₄	0	30	100	96.8	R
4	C_6H_5	Η	[Rh(COD)(S-2a)]BF ₄	0	30	100	96.8	S
5	p - $CF_3C_6H_4$	Η	[Rh(COD)(R-2a)]BF ₄	RT	10	100	97.5	R
6	p - $CF_3C_6H_4$	Η	$[Rh(COD)(R-2a)]BF_4$	0	30	100	99.0	R
*7	p-CF ₃ C ₆ H ₄	H	$[Rh(COD)(R-2a)]BF_4$	0	30	100	98.7	R
8	$p-FC_6H_4$	Η	$[Rh(COD)(R-2a)]BF_4$	RT	10	100	89.6	R
9	p-FC ₆ H ₄	Η	$[Rh(COD)(R-2a)]BF_4$	0	30	100	96.0	R
10	m - $CH_3C_6H_4$	Η	[Rh(COD)(R-2a)]BF ₄	RT	10	100	92.0	R
11	m - $CH_3C_6H_4$	Η	[Rh(COD)(R-2a)]BF ₄	0	30	100	97.7	R
12	p-CH ₃ C ₆ H ₄	Η	[Rh(COD)(R-2a)]BF ₄	RT	10	100	93.2	R
13	p-CH ₃ C ₆ H ₄	Η	[Rh(COD)(R-2a)]BF ₄	0	30	100	97.0	R
14	p-ClC ₆ H ₄	H	[Rh(COD)(R-2a)]BF ₄	RT	10	100	94.0	R
15	p-ClC ₆ H ₄	H	[Rh(COD)(R-2a)]BF ₄	0	30	100	97.0	R
16	2-furanyl	H	[Rh(COD)(R-2a)]BF ₄	RT	10	100	97.4	R
17	2-furanyl	H	[Rh(COD)(R-2a)]BF ₄	0	30	100	98.4	R
18	C_6H_5	CH_3	[Rh(COD)(R-2a)]BF ₄	0	120	83.4	78.3	R
19	p-CH ₃ C ₆ H ₄	CH ₃	[Rh(COD)(R-2a)]BF ₄	0	120	96.6	76.9	R
20	p-ClC ₆ H ₄	CH ₃	[Rh(COD)(R-2a)]BF ₄	0	120	100	80.3	R

Substrate/Catalyst (mole/mole) = 200;

 $P_{H2} = 100 \text{ KPa};$

THF as solvent.

*Substrate/Catalyst (mole/mole) = 1000.

The conversion and e.e. values were determined by GLC with a CHIRASIL-L-VAL column.

-continued

Substrate/Catalyst (mole/mole) = 100;

 $P_{H2} = 200 \text{ KPa};$

room temperature;

time = 10 min;

THF as solvent

The conversion and e.e. values were determined by GLC with a CHIRASIL-L-VAL column.

Entry	R^6	R ⁸	R^7	Cat.	Conv. (%)	e.e. (%)	Config.
1	phenyl	CH ₃	Н	[Rh(COD)(R-2a)]BF ₄	100	94.2	R
2	H	CH_3	Н	$[Rh(COD)(R-2a)]BF_4$	100	99.0	R
3	o-chloro-phenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	94.1	R
4	m-chloro-phenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	92.8	R
5	p-chloro-phenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	93.1	R
6	2-methoxy-phenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	92.5	R
7	4-nitro-phenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	90.0	R
8	3,4-methylene-dioxyphenyl	CH_3	Н	[Rh(COD)(R-2a)]BF ₄	100	91.1	R
9	2-furyl	phenyl	Н	$[Rh(COD)(R-2a)]BF_4$	100	93.9	R

Substrate/Catalyst (mole/mole) = 100;

 $P_{H2} = 200 \text{ KPa};$

room temperature;

time = 10 time;

ethanol as solvent.

The conversion and e.e. values were determined by GLC with a CHIRASIL-L-VAL column after converting to its methyl ester derivative.

15

25

11

We claim:

1. An optically active ligand R-2, R-3, S-2, or S-3 having the following structure:

wherein:


(i) for the ligands of formula R-2 and S-2, R is chosen from the following group:

$$\begin{array}{c|c} & & & \\ \hline \\ & & \\ \\ & & \\ \hline \\ & & \\ \\ & & \\ \hline \\ & & \\ \\ & & \\ \hline \\ & & \\ \\ & &$$

12

in which R' and R" may be the same or different and each represents a straight or branched chain alkyl group having from 1 to 6 carbon atoms or a straight or branched chain alkoxyl group having from 1 to 6 carbon atoms or halogen atoms or haloalkyl, hydroxy, alkanoyl, carboxy, nitro, cyano, amino or mono- or dialkylamino group; and

- (ii) for the ligands of formula R-3 and S-3, R is a cycloalkyl group having from 5 to 8 carbon atoms.
- 2. The ligand of claim 1 comprising
- (R)- or (S)-2,2'-bis(diphenylphospinoamino)-5,5',6,6',7, 7',8,8'-octahydro-1,1'-binaphthyl (R-2a or S-2a):



- 3. A chiral catalyst comprising a transition metal complex having the optically active ligand according to claim 1.
- **4.** A chiral catalyst comprising a transition metal complex ³⁰ having the optically active ligand according to claim **2**.
 - 5. The chiral catalyst according to claim 3 in which the complex is selected from the group consisting of [Rh(COD) (R-2)]X, [Rh(COD)(S-2)]X, [Rh(COD)(R-3)]X and [Rh (COD)(S-3)]X, wherein R-2, S-2, R-3 and S-3 are previously defined, COD represents cyclooctadiene and X is a balancing anion.

* * * * *